Retrospective analysis reveals the prognostic significance of KRAS mutation subtypes and PD-L1 in non-small cell lung cancer, indicating potential for better prognosis.
Key Points
This study aims to evaluate the prognostic impact of KRAS mutation subtypes and their association with PD-L1 expression in non-small cell lung cancer.
Retrospective analysis of 150 patients with KRAS-mutant NSCLC
Assessment of clinicopathological features, KRAS subtypes, PD-L1 expression, and survival outcomes
Estimation of overall survival and progression-free survival using Kaplan–Meier method and Cox regression analyses.
KRAS G12C was the most frequent subtype (40.7%), followed by G12V (20.7%) and G12D (14.7%)
Significant differences in OS among KRAS mutation subtypes (log-rank p = 0.007): G12D 18 months, G12C 11 months, G12V and G12A 9 months, G13 5 months
PD-L1 positivity higher in KRAS G12C, independently associated with improved OS (HR = 0.622; 95% CI, 0.426–0.907; p = 0.014).